1X10^6 unstimulated or PMA and Ionomycin stimulated (in the presence of Brefeldin A) C57BL/6 mouse splenocytes were surface stained with CoraLite® Plus 647 Anti-Mouse CD3 (CL647-65077, Clone: 17A2) and then fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C). Cells were then stained with 0.5 ug PE Anti-Mouse IFN gamma (PE-65153, Clone: XMG1.2).
1X10^6 HeLa cells were surface stained with 0.2 ug Anti-Human CD146 (65181-1-Ig, Clone:P1H12) and APC-conjugated Goat Anti-Mouse IgG at dilution 1:1000. Cells were not fixed.
1X10^6 unstimulated or PMA and ionomycin stimulated (in the presence of Brefeldin A and Monensin) Th1-polarized splenocytes were surface stained with CoraLite® Plus 647 Anti-Mouse CD4 (GK1.5) and then fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C). Cells were then stained with 0.5 ug FITC Plus Anti-Mouse IFN gamma (FITC-65153, Clone: XMG1.2).
1x10^6 unstimulated or PMA and ionomycin stimulated C57BL/6 Th1-polarized splenocytes were intracellularly stained with 0.5 ug Anti-Mouse IFN gamma (65153-1-Ig, Clone: XMG1.2) and FITC anti-rat IgG1 Antibody. Cells were co-stained with 0.5 ug CoraLite® Plus 647 Anti-Mouse CD4 (GK1.5) (CL647-65104, Clone: GK1.5). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).
1x10^6 unstimulated or PMA, Ionomycin and Brefeldin A treated C57BL/6 Th1-polarized splenocytes were intracellularly stained with APC Anti-Mouse CD4 (GK1.5) and 0.25 ug Anti-Mouse IFN-gamma Rabbit Recombinant Antibody (98045-1-RR, Clone:240262C9) and PE-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).
1x10^6 PMA, Ionomycin and Brefeldin A treated(red) or untreated(blank) C57BL/6 Th1-polarized splenocytes were intracellularly stained with 0.25 ug Anti-Mouse IFN-gamma Rabbit Recombinant Antibody (98045-1-RR, Clone:240262C9) and PE-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), or 0.25 ug Isotype Control(blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).
Biolayer interferometry (BLl) kinetic assays of 98045-1-RR against Mouse IFN-gamma were performed. The affinity constant is below 1 pM.
1X10^6 A375 cells were surface stained with 5 ul Atlantic Blue™ Anti-Human CD146 (AB-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul Atlantic Blue™ Anti-Human CD146 (AB-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul Cardinal Red™ Anti-Human CD146 (CR-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul Cardinal Red™ Anti-Human CD146 (CR-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 405 Anti-Human CD146 (CL405-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 405 Anti-Human CD146 (CL405-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 488 Anti-Human CD146 (CL488-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 488 Anti-Human CD146 (CL488-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 unstimulated or PMA and Ionomycin stimulated (in the presence of Brefeldin A) C57BL/6 mouse splenocytes were surface stained with CoraLite® Plus 647 Anti-Mouse CD4 (CL647-65104, Clone: GK1.5) and then fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C). Cells were then stained with 0.25 ug CoraLite® Plus 488 Anti-Mouse IFN gamma (CL488-65153, Clone: XMG1.2).
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 555 Anti-Human CD146 (CL555-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 555 Anti-Human CD146 (CL555-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 647 Anti-Human CD146 (CL647-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 647 Anti-Human CD146 (CL647-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1x10^6 PMA and ionomycin Stimulate C57BL/6 Th1-polarized splenocytes were intracellularly stained with 0.13 ug CoraLite® Plus 647 Anti-Mouse IFN gamma (CL647-65153, Clone:XMG1.2), and 0.13 ug CoraLite® Plus 647 Rat IgG1 Isotype Control (HRPN) (CL647-65212, Clone: HRPN), and 0.13 ug PE Anti-Mouse CD4 (GK1.5) (PE-65104, Clone: GK1.5). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 750 Anti-Human CD146 (CL750-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul CoraLite® Plus 750 Anti-Human CD146 (CL750-65181, Clone:P1H12), or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul FITC Plus Anti-Human CD146 (FITC-65181, Clone: P1H12) (red) or Mouse IgG1 Isotype Control. Cells were not fixed.
1X10^6 A375 cells were surface stained with 5 ul FITC Plus Anti-Human CD146 (FITC-65181, Clone: P1H12) or Mouse IgG1 Isotype Control. Cells were not fixed.
Purity of recombinant TGF beta 1 was determined by SDS-polyacrylamide gel electrophoresis. The protein was resolved in an SDS-polyacrylamide gel in reducing and non-reducing conditions followed by staining with Comassie blue.
Recombinant human TGF beta 1 (HZ-1011) inhibits IL-4 induced proliferation of the HT-2 mouse cell line. HT-2 cells are Balb/c spleen cells activated by sheep erythrocytes in the presence of IL-2. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HT-2 cells were treated with increasing concentrations of recombinant TGF beta 1 for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 0.01-0.17 ng/mL.

Human iPSC-derived microglia (white) residing within an in vivo brain-like organoid environment (blue) derived using HumanKine growth factors (TGF beta 1- HZ-1011, BMP4- HZ-1045, and Thrombopoietin HZ-1248).(Credits- Credit: Simon T. Schafer & Monique Pena, Technical University of Munich, Center for Organoid Systems)
Purity of recombinant human IL-6 was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue
Recombinant human IL-6 (HZ-1019) stimulates dose-dependent proliferation of the 3G12B10 hybridoma cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. 3G12B10 cells were treated with increasing concentrations of recombinant IL-6 for 96 hours. The EC50 range is 0.03-0.24 ng/mL.

Recombinant human IL-6 (HZ-1019) stimulates dose-dependent proliferation of the 7TD1 hybridoma cell line. Cell number was quantitatively assessed by CellTiter® Cell Viability Reagent. 7TD1 cells were treated with increasing concentrations of recombinant IL-6 for 96 hours. The EC50 is <0.5 ng/mL.
Purity of recombinant human VEGF165 was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue
Recombinant human VEGF165 (HZ-1038) induces dose-dependent proliferation of the HUVEC (human umbilical vein endothelial) cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HUVEC cells were treated with increasing concentrations of recombinant VEGF165 for 96 hours. The EC50 was determined using a 4-parameter non-linear regression model. Activity determination was conducted in triplicate on a validated bioassay. The EC50 range is 0.3-3.75 ng/mL.
Purity of recombinant human VEGF121 was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.
Recombinant human VEGF121 (HZ-1204) induces dose-dependent proliferation of the HUVEC (human umbilical vein endothelial) cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HUVEC cells were treated with increasing concentrations of recombinant VEGF121 for 96 hours. The EC50 was determined using a 4-parameter non-linear regression model. Activity determination was conducted in triplicate on a validated bioassay. The EC50 range is less than 15 ng/mL.

Purity of recombinant human Noggin was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.
Recombinant human Noggin (HZ-1118-GMP) inhibits dose-dependent induction of alkaline phosphatase production by BMP-4 in the ATDC-5 mouse chondrogenic cell line. Alkaline phosphatase production was assessed using pNPP as a chromogenic substrate. ATDC-5 cells were treated with increasing concentrations of recombinant human Noggin and 40 ng/mL of BMP-4 (HZ-1045) for 72 hrs hours before lysis and addition of pNPP. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 values range from 1.5-15 ng/mL.